TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BerGenBio ASA ( (BRRGF) ) has issued an announcement.
Oncoinvent ASA announced the expiration of the subscription period for its fully underwritten rights issue, aiming to raise NOK 130 million through the issuance of 260,000,000 new shares. This capital raise supports the company’s ongoing clinical trials and development of Radspherin®, potentially enhancing its market position in radiopharmaceutical cancer therapies.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, targets micro-metastases in the peritoneum using radium-224, offering a unique therapeutic approach with promising early clinical efficacy data and no serious safety concerns reported.
YTD Price Performance: -88.02%
Average Trading Volume: 370,930
Current Market Cap: NOK261.7M
For a thorough assessment of BRRGF stock, go to TipRanks’ Stock Analysis page.